Skip to Main Content

Paper Details

Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.
0
2023
AML, Acute myeloid leukaemia, CD57, CD8, CD8 effector T cells, HLA-DR, ICOS, KLRG1, RNA, T and myeloid cells, acute myeloid leukaemia, anti-PD-1 antibody, graft-versus-leukaemia, haematological AML, patients
Author NameAffiliation
Marco PuntaIRCCS San Raffaele Scientific Institute
Marco PuntaCenter for OMICS Sciences, IRCCS San Raffaele Scientific Institute
  • 1 - 2

Datasets

Release 1.2